Cu entuziasm și profesionalism, Dr. Dan CĂLUGĂRU a format o echipă bine pregătită, care având la dispoziție tehnică medicală performantă, ajută la rezolvarea problemelor oftalmologice, punând întotdeauna accent pe confortul și siguranța pacienților, oferind servicii oftamologice complete la standarde înalte de calitate, atât prin experiența profesională cât și ca nivel al dotării cu aparatură. Echipa beneficiază de suportul și experiența Prof. Univ. Dr. Mihai Călugăru.
Hawk and Harrier: phase 3, multicenter, randomizaed, double-masked trials of brolucizumab for neovascular age-related macular degeneration
April 2020, Vol. 10, Issue 04, pp. 35070-35071
Macular atrophy in neovascular age-related macular degeneration
March 2020, Vol. 10, Issue 03, pp. 34352-34354
Long-term outcomes of switching to aflibercept for treatment-resistant neovacular age-related macular degeneration
February 2020, Vol. 10, Issue 02, pp. 33739-33740
Comment on “Intravitreal conbercept injection for neovascular age-related macular degeneration”
February 2020, Volume 13, Issue 2, p.362-364
Spectral-domain oct predictors of visual outcomes after ranibizumab treatment for macular edema resulting from retinal vein occlusion
January 2020, Volume 10, Issue 01, pp. 33078-33079
The evolution of fibrosis and atrophy and their relationship with visual outcomes in Asian persons with neovascular age-related macular degeneration
December 2019, Volume 09, Issue 12, pp. 32444-32445
Correspondence
December 2019, Volume 39, Issue 12, p. e60–e62
Ten-year treatment outcomes of neovascular age-related macular degeneration from two regions
November 2019, Volume 09, Issue 11, pp. 31351-31352
Optical coherence tomography angiography findings in chronic central serous chorioretinopathy after photodynamic therapy
October 2019, Volume 09, Issue 10, pp. 30921-30923
Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (csc) diagnosed by swept source optical coherence tomography angiography (ss octa)
September 2019, Volume 09, Issue 09, pp.29982-29983
Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion
September 2019, Volume 205, Pages 200–201
Re: Bailey et al: Intralesional macular atrophy in anti-vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial (Ophthalmology. 2019;126:75–86)
September 2019, Volume 126, Issue 9, Pages e71–e72
Multiple Effects Of Intravitreal Aflibercept On Microvascular Regression In Eyes With Diabetic Macular Edema
August, 2019, Volume 09, Issue 08, pp.29071-29072
Comment on "The thickness and volume of the choroid, outer retinal layers and retinal pigment epithelium layer changes in patients with diabetic retinopathy"
August 2019, Volume 12,Issue 08, p.1366-1368
Patient Characteristics of untreated chronic central serous chorioretinopathy patients with focal versus diffuse leakage
July 2019, Volume 09, Issue 07, pp.28800-28801
Loss of peak vision in retinal vein occlusion patients treated for macular edema
July 2019, Volume 09, Issue 07, pp.28783-28784
Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser
June 2019, Volume 11, Issue 06, pp.4439-4440
A two-year study of diffused retinal pigment epitheliopathy treated with half-dose photodynamic therapy guided by simultaneous angiography and optical coherence tomography
June 2019, Volume 11, Issue 06, pp.4480-4481
Randomized Trial Of Wide-Field Guided Prp For Diabetic Macular Oedema Treated With Ranibizumab
June 2019, Volume 11, Issue 06, pp.4876-4877
Ischemic retinal vein occlusion: Characterizing the more severe spectrum of retinal vein occlusion
May–June 2019, Volume 64, Issue 3, Pages 440–441
Predictive Factors of Response to Mineralocorticoid Receptor Antagonist in Nonresolving Central Serous Chorioretinopathy
May 2019, Volume 201, Pages 87–88
Bun venit!
În clinica noastră se tratează peste 3000 de pacienți anual, număr în permanentă creștere, având în vedere progresul științific și tehnic de care echipa Dr. Călugăru este mereu preocupată.
Echipamentele noaste sunt furnizate de către producători consacrați în domeniu: Alcon (S.U.A), Bausch & Lomb (SUA), Blanco (Germania), Brumaba (Germania), Carl Zeiss Meditec (Germania), Spacelabs (S.U.A), Getinge (Suedia), Tomey (Japonia), Melag (Germania), Nidek (Japonia), Briot (Belgia).
Pentru operațiile de reducere a dioptriilor cu laser excimer (Lasek, Prk) nu este nevoie de analize. Pentru toate celelalte intervenții chirurgicale analizele sunt obligatorii.
Analizele necesare pentru operație:
- Hemoleucograma
- Coagulograma
- Glicemie
- Uree
- VSH
- AST
- ALT
- Bilirubina totală
- HVB
- HVC
- HIV
- Consult cardiologic
- EKG
Pentru a reuși vindecarea unui număr cât mai mare de pacienți echipa Dr. Călugăru colaborează cu mai mulți medici specializați în oftalmologie, opticieni și optometriști, cât și cu medicii de familie din zonele învecinate.